Clinical trials: Residual Disease
Acute Lymphoid Leukemia, Philadelphia Chromosome-Negative B-Cell Precursor
Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia
The present study aims at analyzing the response to treatment of adult patients homogeneously treated with supportive care, chemotherapy and blinatumomab.
- Trial name
- LAL2317 (NCT03367299)
- Testing
- Chemotherapy + Blinatumomab
- Where
- 62 sites in Italy
- Volunteers
- 149 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Diabetic Macular Edema
Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab
This is an open-label, Phase I/II study of intravitreally administered ranibizumab either 0.5-mg and/or 2.0-mg in subjects with clinical, angiographic, and ocular coherence tomography (OCT) evidence of diabetic retinopathy with…
- Trial name
- REEF (NCT01292798)
- Testing
- Ranibizumab
- Where
- 5 sites in United States
- Volunteers
- 43 people
- Sponsor
- California Retina Consultants
Colorectal Cancer, Stage III Colon Cancer
French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies.
- Conditions
- Colorectal Cancer, Stage III Colon Cancer, Minimal Residual Disease, Liquid Biopsy
- Trial name
- NCT06287814
- Testing
- Blood sample/lliquid biopsy
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Montpellier
Colon Adenocarcinoma, Colorectal Cancer
Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
This is a phase 1b, prospective, single arm, non-randomized, open-label clinical trial determining the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan in patients with ctDNA positive colon…
- Trial name
- NCT04920032
- Testing
- TAS-102, Irinotecan, Standard Treatment
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of California, Irvine
MRD-positive, Acute Lymphoblastic Leukemia
Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL
To evaluate the safety and efficacy of CD19/CD22 Bispecific chimeric antigen receptor (CAR)-T for the treatment of measurable residual disaese (MRD)-positive B cell acute lymphoblastic leukemia.
- Trial name
- NCT03919526
- Testing
- anti-CD19/CD22 CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Pancreatic Neoplasms
Respiratory-gated Stereotactic Body Radiation Therapy for Adenocarcinoma of the Pancreas or Periampullary Region
This is a single center, single arm unblinded prospective study of the safety of pancreatic stereotactic body radiation therapy (SBRT) in patients with unresectable, borderline resectable, or recurrent pancreatic/periampullary…
- Trial name
- NCT02780648
- Testing
- Stereotactic Body Radiation
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Indiana University
Obesity, Diabetes
Residual Gastric Volume in Morbidly Obesa Diabetics. A Comparison of 3 Hour Versus Hour Fasting.
To reduce the risk of aspiration for elective procedures, residual gastric volumes (RGV) have traditionally been minimized with overnight fasting.
- Conditions
- Obesity, Diabetes, Fasting
- Trial name
- NCT02114008
- Testing
- Endoscopic examinations
- Where
- Brazil
- Volunteers
- 8 people
- Sponsor
- Cuiaba University
Brain and Central Nervous System Tumors
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation or bone marrow transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00025558
- Testing
- filgrastim, carboplatin, temozolomide
- Where
- 4 sites in United States, Australia
- Sponsor
- NYU Langone Health
Amblyopia
Levodopa for the Treatment of Residual Amblyopia
The purpose of this study is to evaluate the efficacy and safety of oral levodopa and patching versus oral placebo and patching as treatment for residual amblyopia in children 7 to <13 years old with visual acuity of 20/50 to…
- Trial name
- ATS17 (NCT01190813)
- Testing
- Levodopa/Carbidopa, Patching
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- Jaeb Center for Health Research
Multiple Myeloma
Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation
To assess whether continued treatment to achieve negative Minimal Residual Disease and Imaging (MRDI(-)) improves therapeutic outcomes in patients with newly diagnosed Multiple Myeloma.
- Trial name
- NCT05697913
- Testing
- Continued treatment adapted to the response
- Volunteers
- 66 people
- Sponsor
- Hospital Galdakao-Usansolo
Neuroma, Cryoablation
Proximal Nerve Cryoablation Versus Perineuroma Cryoablation for Chronic Neuroma Pain After Combat-Related Amputation
atients with combat-related amputations frequently develop chronic neuroma pain that interferes with rehabilitation, prosthesis use, mobility, sleep, and quality of life.
- Trial name
- AXON-FREEZE (NCT07618689)
- Testing
- Perineuroma Cryoablation, Proximal Nerve Cryoablation
- Where
- Ukraine
- Volunteers
- 50 people
- Sponsor
- Ukrainian Society of Regional Anesthesia and Pain Therapy
Type 2 Diabetes
Glucose Response, Excursions And Treatment (GREAT) Study
Patients with type 2 diabetes have very variable endogenous insulin secretion. While some patients have relatively preserved endogenous insulin with marked insulin resistance others may develop the very severe insulin deficiency…
- Trial name
- GREAT (NCT02506296)
- Testing
- DPPIV inhibitor -, Continuous glucose monitoring system.
- Where
- United Kingdom
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Royal Devon and Exeter NHS Foundation Trust
Triple-negative Breast Cancer
Molecular Profiling After Neoadjuvant Chemotherapy for Triple-negative Breast Cancer
Neoadjuvant chemotherapy (NACT) can induce complete pathologic response (pCR) in approximately 35-55% of patient with triple-negative breast cancer (TNBC). These patients have excellent long term survivals.
- Trial name
- NCT04362462
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Texas Tech University Health Sciences Center, El Paso
Triple Negative Breast Cancer
A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer
It is a randomized, open label, positive drug controlled, multicenter design Phase III clinical trial, aims to compare the efficacy and safety of SHR-A1811 combined with Adebrelimab and the treatment selected by the researchers…
- Trial name
- NCT07679360
- Testing
- Trastuzumab Rezetecan for Injection, Adebrelimab Injection, Capecitabine tablets
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Breast Cancer, Hormonreceptor Positive
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
The PENELOPEB study is designed to demonstrate that, in the background of standard anti-hormonal therapy, palbociclib provides superior invasive disease-free survival (iDFS) compared to placebo in pre- and postmenopausal women…
- Conditions
- Breast Cancer, Hormonreceptor Positive, Her2-normal, Postneoadjuvant Treatment With CDK 4/6 Inhibitor
- Trial name
- PENELOPE-B (NCT01864746)
- Testing
- Palbociclib PD-0332991
- Where
- 11 sites in United States, Australia and 9 more
- Volunteers
- 1,250 people
- Sponsor
- GBG Forschungs GmbH
B Acute Lymphoblastic Leukemia, CD19 Positive
Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies
This phase I trial studies the best dose and side effects of CD19/CD22 chimeric antigen receptor (CAR) T cells when given together with chemotherapy, and to see how well they work in treating children or young adults with CD19…
- Conditions
- B Acute Lymphoblastic Leukemia, CD19 Positive, Minimal Residual Disease, Philadelphia Chromosome Positive
- Trial name
- NCT03241940
- Testing
- Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Stanford University
Multiple Myeloma
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
Similar to the paradigm established in other hematologic malignancies that are considered curable, the achievement of MRD(-) status is necessary for long term disease control in MM.
- Trial name
- COMMANDER (NCT05434689)
- Testing
- Iberdomide, Daratumumab, Dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- University of Alabama at Birmingham
Mycosis Fungoides/Sezary Syndrome, Cutaneous T Cell Lymphoma
Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study
Cutaneous T-cell lymphomas (CTCL) are a group of primary cutaneous lymphomas including Mycosis Fungoides (MF) and Sézary syndrome (SS).
- Trial name
- KISS01 (NCT06651203)
- Testing
- Follow-up
- Volunteers
- 460 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Amputation, Adult Disease
Revofit™ System Evaluation on Residual Limb Pain in Amputee Patients
At the early stage of the amputation, the residual limb presents post-surgical fluctuations related to post-operative phase, which would need a frequent prosthetic adjustment.
- Trial name
- NCT04276714
- Testing
- Socket without Revofit system, Socket with Revofit system
- Where
- France
- Volunteers
- 1 people
- Sponsor
- University Hospital, Angers
Liver Cirrhosis, Hepatitis C, Chronic
Prolonged Release Pirfenidone for Advanced Residual Liver Fibrosis (MINERVA).
Prolonged-Release Pirfenidone (PR-PFD) is an anti-fibrogenic and anti-inflammatory molecule used for the treatment of idiopathic pulmonary fibrosis (approved by FDA) and liver fibrosis (approved in Mexico by COFEPRIS).
- Conditions
- Liver Cirrhosis, Hepatitis C, Chronic, Epigenetic Disorder
- Trial name
- NCT05542615
- Testing
- Prolonged-Release Pirfenidone
- Where
- 2 sites in Mexico
- Volunteers
- 60 people
- Sponsor
- University of Guadalajara
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.